ACURX PHARMACEUTICALS, INC. |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.18 USD | -0.46% |
|
+4.66% | -44.26% |
| Apr. 04 | Top Premarket Gainers | MT |
| Mar. 19 | H.C. Wainwright Adjusts Price Target on Acurx Pharmaceuticals to $12 From $14, Keeps Buy Rating | MT |
Valuation
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 44.15 | 46.14 | 52.73 | 34.51 | - | - |
| Enterprise Value (EV) 1 | 44.15 | 46.14 | 52.73 | 34.51 | 34.51 | 34.51 |
| P/E ratio | -2.9 x | -3.55 x | -3.33 x | -2.26 x | -1.33 x | -0.99 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | - | - | - | - | - | 2.15 x |
| EV / Revenue | - | - | - | - | - | 2.15 x |
| EV / EBITDA | - | - | - | - | - | - |
| EV / FCF | -3,483,532 x | - | - | - | - | - |
| FCF Yield | -0% | - | - | - | - | - |
| Price to Book | - | - | - | - | - | - |
| Nbr of stocks (in thousands) | 10,216 | 11,593 | 13,768 | 15,757 | - | - |
| Reference price 2 | 4.321 | 3.980 | 3.830 | 2.190 | 2.190 | 2.190 |
| Announcement Date | 3/16/22 | 3/15/23 | 3/15/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - | - | 16.03 |
| EBITDA | - | - | - | - | - | - | - |
| EBIT 1 | - | -12.81 | -12.09 | -14.58 | -15.6 | -26.06 | -17.45 |
| Operating Margin | - | - | - | - | - | - | -108.84% |
| Earnings before Tax (EBT) 1 | - | -12.75 | -12.09 | -14.58 | -15.6 | -28.58 | -41.28 |
| Net income 1 | -4.6 | -12.75 | -12.09 | -14.58 | -15.6 | -26.06 | -17.45 |
| Net margin | - | - | - | - | - | - | -108.84% |
| EPS 2 | -0.7500 | -1.490 | -1.120 | -1.150 | -0.9700 | -1.645 | -2.220 |
| Free Cash Flow | - | -12.67 | - | - | - | - | - |
| FCF margin | - | - | - | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - |
| Announcement Date | 4/5/21 | 3/16/22 | 3/15/23 | 3/15/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EBIT 1 | -2.627 | -2.67 | - | -3.542 | -3.261 | -2.903 | -3.445 | -3.115 | -5.115 | -3.8 | -3.2 | -2.9 | -5.7 |
| Operating Margin | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Earnings before Tax (EBT) 1 | -2.627 | -2.67 | - | -3.542 | -3.261 | -2.903 | -3.445 | -3.115 | -5.115 | -3.8 | -3.2 | -2.9 | -5.7 |
| Net income 1 | -2.627 | -2.67 | -2.621 | -3.542 | -3.261 | -2.903 | -3.445 | -3.115 | -5.115 | -3.8 | -3.2 | -2.9 | -5.7 |
| Net margin | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EPS 2 | -0.2200 | -0.2600 | -0.2600 | -0.3200 | -0.2800 | -0.2500 | -0.2800 | -0.2400 | -0.3800 | -0.2400 | -0.2000 | -0.1800 | -0.3500 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 3/16/22 | 5/10/22 | 8/12/22 | 11/10/22 | 3/15/23 | 5/12/23 | 8/11/23 | 11/13/23 | 3/15/24 | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - | - | - |
| Net Cash position | - | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - |
| Free Cash Flow | - | -12.7 | - | - | - | - | - |
| ROE (net income / shareholders' equity) | - | - | - | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - | - |
| Book Value Per Share | - | - | - | - | - | - | - |
| Cash Flow per Share | - | - | - | - | - | - | - |
| Capex | - | - | - | - | - | - | - |
| Capex / Sales | - | - | - | - | - | - | - |
| Announcement Date | 4/5/21 | 3/16/22 | 3/15/23 | 3/15/24 | - | - | - |
1USD in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
2.19
USD
Average target price
11.45
USD
Spread / Average Target
+422.83%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -44.26% | 34.51M | |
| +0.44% | 42.86B | |
| +12.46% | 42.74B | |
| +44.30% | 41.36B | |
| -6.20% | 27.68B | |
| +6.24% | 25.15B | |
| -23.65% | 18.63B | |
| +27.30% | 12.37B | |
| -3.41% | 11.92B | |
| +7.18% | 11.21B |
- Stock Market
- Equities
- ACXP Stock
- Financials Acurx Pharmaceuticals, Inc.
